License, Collaboration and Service Agreements - Additional Information (Detail) $ / shares in Units, £ in Millions		1 Months Ended				3 Months Ended						12 Months Ended
	Jan. 15, 2021 USD ($)	Jun. 30, 2017 USD ($)	Jun. 30, 2016 USD ($)	Jun. 30, 2016 GBP (£)	May 31, 2016 USD ($)	Mar. 31, 2024 USD ($) $ / shares shares	Mar. 31, 2023 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2020 USD ($)	Mar. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2023 USD ($) $ / shares	Dec. 31, 2022 USD ($)	Sep. 30, 2023 USD ($)	Jul. 31, 2023 USD ($)	Nov. 07, 2022 USD ($)	Oct. 31, 2017 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Common stock, par value | $ / shares						$ 0.001						$ 0.001
Revenue recognized						$ 140,000	$ 223,000
Milestone payment						225,000,000
Total Milestone												$ 95,000,000
Deferred revenue, current						2,868,000						2,132,000
GSK SPA [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Remaining transaction price allocated to the performance obligations						64,700,000
Milestone payment						21,200,000
Total Milestone						30,000,000
Initial Payments to Perform the Obligations													$ 66,000,000
Discount on Obligations													1,300,000
GSK SPA [Member] | Research And Development Services Related To Upcoming Milestones [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized													19,000,000
GSK SPA [Member] | License and Know-How Transfer [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Remaining transaction price allocated to the performance obligations													64,700,000
Performance Obligation Allocated Transaction Price													45,700,000
Vertex License Agreement [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License agreement research and development expense related to achievement of regulatory milestones						$ 0	0
Contract termination period						10 years
Nonrefundable upfront payments					$ 500,000
Potential milestone payment upon achievement of specified clinical, regulatory and commercial milestones					$ 80,200,000
Contract termination period if no material development or commercialization occurs						1 year
GSK License Agreement [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Performance Obligation Allocated Transaction Price						$ 4,100,000	500,000
Deferred revenue, current						44,500,000
GSK License Agreement [Member] | Research And Development Services Related To Upcoming Milestones [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total potential additional milestones												3,200,000
GSK License Agreement [Member] | Glaxo Smith Kline [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment												23,800,000			$ 4,300,000	$ 66,000,000
Reduction In Subsequent Payments by GSK to the Company																50.00%
GSK License Agreement [Member] | GSK SPA [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment						23,800,000						64,700,000			$ 30,000,000
Total Received Milestone												95,000,000		$ 30,000,000
Significant financing component												2,500,000
Total Milestone												95,000,000
Research and development services performance obligation						8,800,000						2,500,000
Meiji License Agreement [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Nonrefundable upfront payments		$ 600,000
Sublicense fee payable to counter party													7,500,000
Potential milestone payments upon achievement of specified condition																	$ 1,000,000
License agreement fixed assets related payments											$ 1,600,000
Potential milestone payments upon completion and delivery of results of a clinical study						1,000,000
Future milestone payments						1,000,000
Sublicence Fee Paid to Counter Party													$ 6,600,000
Remaining Sublicence Fee Paid to Counter Party												$ 900,000
Cantab Related Agreements [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Potential milestone payment upon achievement of specified commercial milestone				£ 5.0		6,300,000
License agreement research and development expense related to achievement of regulatory milestones						$ 0	0
Potential milestone payment upon achievement of specified clinical, regulatory and commercial milestones			$ 5,800,000
Everest License Agreement [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Period of option granted on an agreement						12 months
Upfront payment received										$ 3,000,000
Potential milestone payments upon completion and delivery of results of a clinical study									$ 2,000,000
Revenue recognized						$ 0	0
Milestone payment						34,000,000
Everest License Agreement [Member] | SPR 206 [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment received										2,000,000
Milestones payment received	$ 2,000,000
Everest License Agreement [Member] | SPR 741 [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment received										$ 1,000,000
Everest License Agreement [Member] | Maximum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Agreement termination period upon written notice	180 days
Everest License Agreement [Member] | Maximum [Member] | SPR 206 [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Receivable amount upon achievement of certain milestone	$ 38,000,000					$ 59,500,000
Everest License Agreement [Member] | Minimum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Agreement termination period upon written notice	90 days
Pfizer License and Share Purchase Agreements [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Receivable amount upon achievement of certain milestone								$ 900,000
Milestones payment received								5,000,000
Issuance of stock, shares | shares						2,362,348
Issuance of stock, value						$ 27,500,000
Remaining transaction price allocated to the performance obligations						12,500,000
Revenue recognized						100,000	$ 200,000
Premium associated freestanding equity						12,500,000
Performance Obligation Allocated Transaction Price								5,000,000
Deferred revenue, current						12,800,000
Pfizer License and Share Purchase Agreements [Member] | SPR 206 [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Receivable amount upon achievement of certain milestone						$ 80,000,000
Issuance of stock, shares | shares						2,362,348
Share price | $ / shares						$ 16.93
Proceeds from sale of common stock to related party						$ 40,000,000
Pfizer License and Share Purchase Agreements [Member] | Research And Development Services Related To Upcoming Milestones [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Performance Obligation Allocated Transaction Price						11,100,000		$ 4,100,000
Pfizer License and Share Purchase Agreements [Member] | License and Know-How Transfer [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Performance Obligation Allocated Transaction Price						$ 1,400,000